On December 31, Gelonghui reported that NLS Pharmaceutics (NLSP.US) fell over 12%, closing at $2.39; the stock had soared nearly 50% overnight. In terms of news, the Swiss biopharmaceutical company focused on treating nervous system diseases, NLS, announced yesterday that it has submitted an F-4 registration statement to the SEC outlining the prospectus for its merger agreement with cell therapy company Kadimastem. If the merger is completed, Kadimastem will become a wholly-owned subsidiary of NLS and will be listed on Nasdaq. (Gelonghui)